[First-line treatment of unresectable, stage IV transitional cell carcinoma].
AUO Geschäftsstelle, MeckEvidence - Dienstleistungen für medizinische Dokumentation und Forschung, Seestr. 11, 17252, Schwarz, Deutschland. auo.presse@MeckEvidence.de.
H
H
Rexer
Klinik für Urologie und Kinderurologie, Universitätsklinikum des Saarlandes, Arbeitsgemeinschaft Urologische Onkologie e. V., Homburg/Saar, Deutschland.
C
C
Ohlmann
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D015653:Cystectomy; D019317:Evidence-Based Medicine; D005260:Female; D005858:Germany; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D055815:Young Adult
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C000613593:durvalumab; C520704:tremelimumab